Hyperlipidemia is a well-known risk factor for cardiovascular diseases (CVDs). Coronary heart disease, stroke, and atherosclerosis are among the primary cause of death. Various medicines are available for the treatment of hyperlipidemia however, they are linked with serious unwanted effects. Zingiber officinale L. extract (Ginger) was used in folklore medicine as a hypolipidemic agent, Although, its clinical trial studies were not been investigated in the Pakistani population yet. Our clinical study is the first to assess the hypolipidemic, antioxidant, and cardioprotective effect of ginger tablets on dyslipidemic patients regarded as important risk factors for cardiovascular morbidity. A total of 40 dyslipidemic patients of age (18-65 years) of either sex were recruited in Al-Khidmat Hospital Karachi and allocated into two groups; the Simvastatin group (20 mg OD) and the Ginger treated group (500mg Ginger tablets BD) for 2 months. At baseline, their Blood pressure (BP), heart rate (HR), Insomnia severity index (ISI), Minimental state examination (MMSE), Lipid profile, Serum Glutamic Oxaloacetic Transaminase (SGOT), Serum Glutamic Pyruvic Transaminase (SGPT), creatine kinase (CK-MB), C-reactive protein, Superoxide Dismutase (SOD) \& Glutathione Peroxidase (GPx) were recorded and repeated after 2 months of follow-up.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assessment of total lipid profile
Timeframe: baseline to 2 month
Assessment of cardio protective profile
Timeframe: baseline to 2 month